← Back to Clinical Trials
Recruiting NCT06556654

NCT06556654 Tissue Reinforcement for Breast Reconstruction (TRBR) Pivotal Clinical Study (REDEFINE)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06556654
Status Recruiting
Phase
Sponsor W.L.Gore & Associates
Condition Breast Reconstruction Surgery
Study Type INTERVENTIONAL
Enrollment 180 participants
Start Date 2025-04-09
Primary Completion 2027-07

Trial Parameters

Condition Breast Reconstruction Surgery
Sponsor W.L.Gore & Associates
Study Type INTERVENTIONAL
Phase N/A
Enrollment 180
Sex FEMALE
Min Age 22 Years
Max Age N/A
Start Date 2025-04-09
Completion 2027-07
Interventions
TRBR Device

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The GORE Tissue Reinforcement for Breast Reconstruction (TRBR) research study will look at breast reconstruction during mastectomy procedures. There will be two arms in this study, a Treatment Arm, where data will be collected for a new medical device called the Tissue Reinforcement for Breast Reconstruction (TRBR) Device and a Control Arm where data will be collected from subjects who have previously had surgery and received no additional tissue reinforcement in their breast reconstruction surgery. This research study will look at the safety of the Study Device and the success of the participants breast reconstruction. The Study Device is investigational, which means it has not yet been used nor approved by the FDA for this treatment. The data collected in this study will be compared to the data collected in the Control Arm.

Eligibility Criteria

Inclusion Criteria: 1. Female subjects ≥ 22 years of age. 2. First-time breast reconstruction post-mastectomy for target breast(s). 3. Scheduled to undergo unilateral or bilateral mastectomy with immediate, two-stage, implant-based, subpectoral or prepectoral breast reconstruction after mastectomy. 4. Mastectomy performed to address breast cancer or for cancer prophylaxis. 5. An informed consent form is signed by Subject or Legally Authorized Representative (LAR). 6. Subject is capable of following protocol procedures and complying with follow-up visit requirements Exclusion Criteria: Baseline Exclusion Criteria 1. Subject has had a revision(s) in the target breast(s) following complications of breast augmentation, mastopexy (breast lift), or breast reduction. 2. Subject has undergone previous radiation therapy to the reconstruction site or chest wall. 3. Subject has had chemotherapy within 3 weeks prior to the index procedure. 4. Subject has been treated for a systemic infection or lo

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology